A detailed history of Montag A & Associates Inc transactions in Dexcom Inc stock. As of the latest transaction made, Montag A & Associates Inc holds 650 shares of DXCM stock, worth $42,692. This represents 0.0% of its overall portfolio holdings.

Number of Shares
650
Previous 555 17.12%
Holding current value
$42,692
Previous $76,000 3.95%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$110.31 - $140.45 $10,479 - $13,342
95 Added 17.12%
650 $73,000
Q1 2024

May 07, 2024

SELL
$114.22 - $140.1 $6,853 - $8,406
-60 Reduced 9.76%
555 $76,000
Q4 2023

Feb 07, 2024

SELL
$75.49 - $124.16 $305,055 - $501,730
-4,041 Reduced 86.79%
615 $76,000
Q3 2023

Nov 09, 2023

BUY
$86.06 - $137.93 $56,197 - $90,068
653 Added 16.31%
4,656 $434,000
Q2 2023

Aug 09, 2023

BUY
$112.47 - $130.98 $19,457 - $22,659
173 Added 4.52%
4,003 $514,000
Q1 2023

May 11, 2023

SELL
$104.0 - $122.92 $56,576 - $66,868
-544 Reduced 12.44%
3,830 $444,000
Q4 2022

Feb 02, 2023

BUY
$84.98 - $122.67 $65,094 - $93,965
766 Added 21.23%
4,374 $495,000
Q3 2022

Nov 09, 2022

SELL
$76.35 - $94.18 $254,703 - $314,184
-3,336 Reduced 48.04%
3,608 $291,000
Q2 2022

Aug 10, 2022

SELL
$67.99 - $132.89 $296,640 - $579,799
-4,363 Reduced 38.59%
6,944 $518,000
Q1 2022

May 02, 2022

BUY
$94.08 - $130.2 $12,794 - $17,707
136 Added 1.22%
11,307 $5.79 Million
Q4 2021

Feb 09, 2022

BUY
$129.87 - $162.82 $32,337 - $40,542
249 Added 2.28%
11,171 $1.5 Million
Q3 2021

Nov 08, 2021

BUY
$106.71 - $143.18 $1.17 Million - $1.56 Million
10,922 New
10,922 $5.97 Million
Q1 2021

May 14, 2021

SELL
$84.79 - $104.74 $5,426 - $6,703
-64 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$78.0 - $104.5 $4,992 - $6,688
64 New
64 $24,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $25.4B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Montag A & Associates Inc Portfolio

Follow Montag A & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Montag A & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Montag A & Associates Inc with notifications on news.